Patents Examined by Sean Aeder
-
Patent number: 10526406Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.Type: GrantFiled: January 14, 2015Date of Patent: January 7, 2020Assignee: CELLECTISInventors: Philippe Duchateau, Julien Valton
-
Patent number: 9856327Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: June 17, 2016Date of Patent: January 2, 2018Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 9850320Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: June 17, 2016Date of Patent: December 26, 2017Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 9801928Abstract: It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.Type: GrantFiled: June 23, 2015Date of Patent: October 31, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang
-
Patent number: 9797905Abstract: The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.Type: GrantFiled: March 2, 2016Date of Patent: October 24, 2017Assignee: Berg LLCInventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Vivek K. Vishnudas
-
Patent number: 9789159Abstract: The methods of the present disclosure are directed toward methods of diagnosis and treatment of cancer in a subject. The present disclosure provides methods of diagnosing abnormal cells in a subject by measuring the level of Hexim-1 in a sample from the subject, where elevated levels of Hexim-1 indicate abnormal cells. This disclosure further provides methods of treating cancer or hyperplasia, comprising administering to a subject in need thereof a therapeutically effective amount of Hexim-1 or an activator of Hexim-1 expression or activity.Type: GrantFiled: March 22, 2012Date of Patent: October 17, 2017Assignee: The Research Foundation for The State University of New YorkInventors: Manya Dhar-Mascareno, Eduardo J. Mascareno
-
Patent number: 9758829Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.Type: GrantFiled: June 24, 2013Date of Patent: September 12, 2017Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer InstituteInventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
-
Patent number: 9753035Abstract: The present invention relates to DNA sequences from regions of copy number change on chromosome 20. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases.Type: GrantFiled: September 11, 2007Date of Patent: September 5, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Daniel Pinkel, Donna G. Albertson, Joe W. Gray
-
Patent number: 9744184Abstract: The present invention relates to a trehalulose-containing composition, its preparation and use.Type: GrantFiled: April 15, 2010Date of Patent: August 29, 2017Assignee: SUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURTInventors: Wolfgang Wach, Thomas Rose, Michael Klingeberg, Siegfried Peters, Tillmann Dörr, Stephan Theis, J{dot over (o)}rg Kowalczyk, Stephan Hausmanns
-
Patent number: 9745364Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: GrantFiled: January 20, 2012Date of Patent: August 29, 2017Assignee: The Feinstein Institute for Medical ResearchInventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Patent number: 9738936Abstract: It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and ovarian cancers. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to the GT198 gene mutations. Another embodiment provides methods and compositions for detecting cancer due to the mutation of the GT198 gene. Still another embodiment provides methods for identifying compounds, antibodies and natural product molecules that are useful for treating cancer due to the mutations of the GT198 gene. Preferably the disclosed compositions antagonize or interfere with the biological activity of splice variants of GT198.Type: GrantFiled: June 19, 2013Date of Patent: August 22, 2017Inventor: Lan Ko
-
Patent number: 9726661Abstract: The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as ?133TP53, TP53?, TP53? or ?40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.Type: GrantFiled: July 8, 2013Date of Patent: August 8, 2017Assignee: Institut Gustave-RoussyInventors: Jean-Luc Perfettini, Guido Kroemer, Eric Deutsch
-
Patent number: 9719984Abstract: The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.Type: GrantFiled: April 7, 2014Date of Patent: August 1, 2017Assignee: ONCIMMUNE LTD.Inventors: John Forsyth Russell Robertson, Anthony Barnes, Andrea Murray, Caroline Chapman
-
Patent number: 9721067Abstract: An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures.Type: GrantFiled: November 1, 2013Date of Patent: August 1, 2017Assignee: UNIVERSITY OF NOTRE DAME DU LACInventor: Steven Buechler
-
Patent number: 9714938Abstract: The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.Type: GrantFiled: April 7, 2014Date of Patent: July 25, 2017Assignee: ONCIMMUNE LTD.Inventors: John Forsyth Russell Robertson, Anthony Barnes, Andrea Murray, Caroline Chapman
-
Patent number: 9713648Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.Type: GrantFiled: November 11, 2015Date of Patent: July 25, 2017Assignee: Seattle Genetics, Inc.Inventors: Eric Sievers, Dana Kennedy
-
Patent number: 9707249Abstract: A trehalulose-containing composition, its preparation and use.Type: GrantFiled: November 20, 2013Date of Patent: July 18, 2017Assignee: SUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURTInventors: Wolfgang Wach, Thomas Rose, Michael Klingeberg, Siegfried Peters, Tillmann Dörr, Stephan Theis, Jörg Kowalczyk, Stephan Hausmanns
-
Patent number: 9702878Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.Type: GrantFiled: March 15, 2013Date of Patent: July 11, 2017Assignees: Fundació Institut de Recera Biomèdica (IRB Barcelona), Institució Catalana de Recerca I Estudis AvançatsInventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
-
Patent number: 9701759Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.Type: GrantFiled: January 14, 2014Date of Patent: July 11, 2017Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
-
Patent number: 9694072Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.Type: GrantFiled: October 27, 2014Date of Patent: July 4, 2017Assignee: Trustees of Dartmouth CollegeInventor: William G. North